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MicroRNA-125b (miR-125b) is up-regulated in patients with leukemia.
Overexpression of miR-125b alone in mice causes a very aggressive,
transplantable myeloid leukemia. Before leukemia, these mice do not
display elevation of white blood cells in the spleen or bone marrow;
rather, the hematopoietic compartment shows lineage-skewing, with
myeloid cell numbers dramatically increased and B-cell numbers
severely diminished. miR-125b exerts this effect by up-regulating the
number of common myeloid progenitors while inhibiting develop-
ment of pre-B cells. We applied a miR-125b sponge loss of function
system in vivo to show that miR-125b physiologically regulates
hematopoietic development. Investigating the mechanism by which
miR-125b regulates hematopoiesis, we found that, among a panel of
candidate targets, the mRNA for Lin28A, an induced pluripotent stem
cell gene, was most repressed by miR-125b in mouse hematopoietic
stem and progenitor cells. Overexpressing Lin28A in the mouse
hematopoietic system mimicked the phenotype observed on inhibit-
ingmiR-125b function, leading to a decrease in hematopoietic output.
Relevant to the miR-125b overexpression phenotype, we also found
that knockdown of Lin28A led to hematopoietic lineage-skewing,
with increased myeloid and decreased B-cell numbers. Thus, the miR-
125b target Lin28A is an important regulator of hematopoiesis and
a primary target of miR-125b in the hematopoietic system.
cancer | myelogenous | lymphocyte
MicroRNA-125b (miR-125b) is up-regulated in a range ofhuman leukemias, including acute myeloid leukemia (1, 2),
chronic myeloid leukemia (2), acute megakaryocytic leukemia (3),
childhood acute lymphoblastic leukemia with the ETV6/Runx1
fusion protein (4), and Philadelphia chromosome-positive B-cell
precursor childhood acute lymphoblastic leukemia (2). Indeed,
overexpression of miR-125b alone in the bone marrow of mice is
sufﬁcient to induce leukemia (2, 5, 6). Recent in vitro work has also
uncovered a role for miR-125b in the development of plasma cells
(7) and effector T cells (8), suggesting that miR-125b regulates
immune cell development in addition to promoting leukemia.
Lin28A is an important regulator of early embryogenesis in
mice and humans (9). Levels of Lin28A are enriched in ES cells
and decrease as these cells differentiate (9). Ectopic expression of
Lin28A along with three other genes (Oct4, Sox2, and Nanog)
causes dedifferentiation of mature human cells into induced
pluripotent stem cells (10). This shows the power of Lin28A to
endow cells with pluripotent qualities. Still, it remains to be seen
whether Lin28A also plays developmental roles in biological
systems arising from adult stem cells, such as hematopoiesis.
In this study, we examine the role of miR-125b in inducing
cancer and show that overexpression of this microRNA induces
a preleukemic state before aggressive frank leukemia is evident.
This preleukemic state is characterized by overproduction of
myeloid cells and their precursors as well as inhibition of B-cell
development. We then show that the most affected target gene of
miR-125b is Lin28A and that Lin28A down-regulation can mimic
the preleukemic state induced by miR-125b. Furthermore, down-
regulation of miR-125b has profound effects on normal hema-
topoiesis, and Lin28A overexpression mimics those effects.
Results
miR-125b Ectopic Expression Favors Myeloid Differentiation and
Causes a Highly Invasive Myeloid Leukemia. Previously, we showed
that overexpression of miR-125b in bone marrow-transplanted
recipient mice causes a myeloid leukemia 4–6 mo after bone
marrow reconstitution (5). Here, we found that the neoplastic
myeloid cells inﬁltrate nonhematopoietic organs, including the
brain, and overwhelm the periphery (Fig. 1 and Figs. S1 and S2).
Mice overexpressing miR-125a also developed an aggressive
leukemia that was shown by enlarged spleen and cancer in-
ﬁltration into the liver and kidneys (Fig. S3). These mice died by
6 mo postreconstitution. Thus, dysregulated expression of miR-
125b or its paralogue leads to an aggressive leukemia that efﬁ-
ciently invades nonhematopoietic organs.
To understand the initial events that precede the frank leu-
kemia, we examined the spleen and bone marrow at 7 wk after
reconstitution, a time well before the onset of cancer as indicated
by similar white blood cell counts in the spleen (∼100 million
cells for both MG and 125b spleens) and bone marrow of control
MG (murine stem cell virus-GFP retro-vector) and MG-125b
animals (Fig. 2A and Fig. S4 A and B). At this time, MG-125b
animals showed dramatic increases in all myeloid lineages, in-
cluding granulocytes, macrophages, and dendritic cells, with T-
cell numbers being similar to those in the MG mice (Fig. 2A and
Fig. S4 C–E). However, B-cell numbers were signiﬁcantly de-
creased in these miR-125b–overexpressing animals (Fig. 2A and
Fig. S4F). Whether miR-125b physiologically regulates B-cell
development will require additional studies. Thus, miR-125b
overexpression at the precancerous stage causes a lineage-
skewing of the hematopoietic compartment with myeloid cell
numbers elevated and B cells diminished.
To investigate the developmental stage at which miR-125b
overexpression promotes myelopoiesis and compromises B-cell
development, we analyzed hematopoietic stem and progenitor
cell (HSPC) numbers in the bone marrow at 7 wk after bone
marrow transplantation. In these mice, the hematopoietic stem
cell (HSC) numbers were similar in MG-125b animals compared
with MG controls (Fig. S4 G and H). Progenitors directly
downstream of HSCs, however, including multipotent progeni-
tors (MPPs), common myeloid progenitors and granulocyte
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macrophage progenitors (CMPs/GMPs), myeloid–erythroid pro-
genitors (MEPs), and common lymphoid progenitors (CLPs),
were all signiﬁcantly increased (Fig. 2B). Of these progenitors,
CMPs/GMPs were the most drastically augmented, being ele-
vated 8.4-fold in MG-125b animals compared with controls (Fig.
2B). Notably, pre–B-cell numbers were severely decreased (Fig.
2B), providing a developmental basis for the decreased B-cell
numbers that we observed in MG-125b animals. This ﬁnding also
indicates that miR-125b overexpression causes a developmental
block between the CLP and pre–B-cell stages. In summary, we
show here that, before the onset of leukemic disease, miR-125b
skews hematopoietic differentiation to the myeloid lineage likely
by increasing CMP/GMP and blocking B-cell development.
Physiological Regulation of Hematopoiesis by miR-125b. Although
overexpression studies are relevant to the role of miR-125b as an
oncomiR, we developed a loss of function system to assess the
potential physiological role of miR-125b in hematopoiesis. We
generated a sponge decoy to competitively inhibit miR-125b
binding to its natural targets (11–14) (Fig. S5A). Of note, the
sponge does not decreasemiR-125b expression, but rather, it serves
as a decoy to compete miR-125b away from endogenous targets.
Indeed, the sponge decoy (MG sponge) was capable of signiﬁcantly
derepressing a luciferase reporter vector containing an artiﬁcial 3′
UTR with two perfect miR-125b complementary sequences (Fig.
S5B). Showing the effectiveness of this approach, a UTR-less re-
porter vector was not derepressed by the sponge (Fig. S5C). To
determine the hematopoietic effect of miR-125b loss of function,
recipient mice were reconstituted with equal numbers of sorted
GFP+ MG and MG sponge-transduced bone marrow cells (Fig.
S5D). The MG sponge mice at 1 mo postreconstitution had sig-
niﬁcantly fewer white blood cells (CD45+), myeloid cells (CD45+
CD11b+), pre-erythrocytes (CD45+ Ter119+), and granulocytes
(CD45+Gr1+) comparedwith theMGcontrols (Fig. 3). The blood
was also noticeably thinner in the sponge mice compared with
controls, indicating that mature erythrocytes were decreased as
well. The sponge data indicate an important physiological role for
miR-125b in hematopoietic development, whereas the over-
expression data show that excess levels lead to cancer.
Lin28A Is a Primary Target of miR-125b in the Hematopoietic System.
To identify miR-125b targets that might regulate hematopoietic
development, we performed an unbiased screen using Targetscan
(15–17) to isolate putative miR-125b targets with PConserved Targeting
> 0.8 (P > 0.8 that the putative microRNA site is evolutionarily
maintained because of selective microRNA targeting rather than
chance) (17). Application of this screen yielded 192 genes. Gene
ontology analyses indicate that these genes are functionally en-
riched for biological processes that include transcriptional regu-
lation, vasculature development, proteolysis, and apoptosis (Da-
vid Functional Annotation Bioinformatics, P < 0.05). We focused
on the processes that were proapoptotic or involved with stem cell
regulation, because these processes have been correlated with
leukemic development. This focus yielded four candidate genes
(Bak1, Trp53inp1, BMF, and Lin28A) that, independently, have
been previously validated as miR-125b targets by other groups (2,
18–20). We examined and conﬁrmed by quantitative PCR that
miR-125b represses these genes, including Lin28A, in 5-ﬂuoro-
uracil (5-FU)–treated bone marrow hematopoietic cells enriched
for HSPCs (Fig. 4A). As evidence of these genes being miR-125b
direct targets, we found that the 3′ UTR luciferase reporter of
all of these genes, but not the negative control Picalm, was sig-
niﬁcantly repressed by miR-125b overexpression (Fig. 4B).
Notably, endogenous expression of Lin28A, Trp53inp1, and
BMF was derepressed by the miR-125b sponge decoy in HSPC-
enriched bone marrow (Fig. S6A). The miR-125b sponge decoy
also derepressed ﬁvefold a luciferase reporter containing the
mouse Lin28A 3′ UTR (Fig. 4C), which contains a 9-nt miR-
125b seed sequence (Fig. S6B). Showing that the miR-125b:
Lin28A interaction exhibits species conservation between
mouse and human hematopoietic cells, human myeloid K562
cells transduced with MG-puromycin retro-vector (MGP),
MGP-125b-1, MGP-125b-2, or a seed mutant of miR-125b
exhibited seed-dependent repression of Lin28A by both miR-
125b species at both the RNA and protein levels (Fig. 4D and
Fig. S6 C–E). Of note, the expression of the Lin28B isoform was
not repressed by miR-125b (Fig. S6 F andG). In summary, miR-
125b directly represses Lin28A in hematopoietic cells, an in-
teraction conserved between mouse and human. Previously, up-
regulation of Lin28A and Lin28B has been associated with
cancer development (21). Thus, we examined the expression of
these genes in leukemic samples overexpressing miR-125b but
found that Lin28A and Lin28B expression was similar in the
cancer samples and control cells (Fig. S7).
Fig. 1. miR-125b overexpression causes an aggressive in-
vasive myeloid leukemia. (A) Inﬁltration of GFP+ CD45+ and
GFP+ CD11b+ cells into the brain. (Upper) Representative ﬂow
cytometric plots are shown. (Lower) Average percent GFP+
CD45+ and GFP+ CD11b+ in the brain are shown from three
MG and twoMG-125b mice. (B) Leukemic cell inﬁltration into
nonhematopoietic organs. Sections from the kidney, lung,
and liver were stained with H&E. The normal structures of
the MG-125b mouse kidney, lung, and liver are effaced by
a dramatic inﬁltrate of leukemic cells. A representative im-
age for each tissue is shown. The brain, kidney, lung, and
liver were harvested from animals 5 mo after bone marrow
reconstitution. During the time of harvest, the average per-
cent GFP+ cells in the spleens of MG and MG-125b mice were
49 ± 9.7% and 91 ± 2.9%, respectively. All plots shown depict
the mean with SEM. All data are representative of two
independent experiments. Inf, inﬁltrate; G, glomerulus; A,
alveolar space; CV, central vein.
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Lin28A Regulates Aspects of Hematopoiesis That Mirror Those
Controlled by miR-125b. The regulation of Lin28A by miR-125b
is highly conserved across species. The Caenorhabditis elegans
homolog of miR-125b Lin-4 also represses the RNA binding
protein Lin28A. The Lin-4:Lin28A cascade has been shown to be
critical for proper worm development. However, a potential
critical developmental function of miR-125b:Lin28A signaling in
mammals has not yet been explored. In addition, Lin28A is known
to be involved inmaintaining pluripotency of ES cells, but its role in
other biological events, such as hematopoiesis, has not been fully
characterized. Thus, we were interested in determining whether
miR-125b–mediated repression of Lin28A has a role in the he-
matopoietic system. We bypassed the repressive effect exerted by
endogenous miR-125b by overexpressing Lin28A lacking its 3′
UTR. We used the murine stem cell virus (MSCV)-internal ribo-
some entry site (IRES)-GFP (MIG) vector system (22), which
allowed the coexpression of Lin28A and GFP from the same
vector. A Western blot was performed to conﬁrm expression of
Lin28A from the MIG-Lin28A vector in transfected 293T cells
(Fig. S8A). Next, we performed bone marrow transplant experi-
ments with HSPC-enriched bone marrow cells transduced with
either MIG or MIG-Lin28A. We achieved over 80% transduction
efﬁciency as measure by GFP-positive cells (Fig. S8B). Similar to
mice reconstituted with the miR-125b sponge decoy (Fig. 3), ani-
mals with Lin28A overexpression had signiﬁcant decreases in total
white blood cells (CD45+), total myeloid cells (CD45+ CD11b+),
granulocytes (CD45+ Gr1+), and erythrocytes (Ter119+ CD11b−)
(Fig. 5). Also similar to the sponge mice, the blood was noticeably
thinner from MIG-Lin28A animals compared with MIG controls,
likely because of the diminished erythrocyte numbers that we ob-
served. Of importance, whereas all of the controls remained
healthy, the Lin28A overexpressing mice with the thinnest blood (2
of 15) died at 5 wk postreconstitution, likely as a consequence
of impaired hematopoietic development. Thus, overexpressing
Lin28A in the hematopoietic system mirrored the phenotypes
observed on miR-125b inhibition (Fig. 3).
Next, we used Lin28A loss of function studies to examine
whether Lin28A physiologically regulates hematopoiesis. Also,
A
B
Fig. 2. miR-125b overexpression causes a skewing of the hematopoietic system at 7 wk postreconstitution of bone marrow. (A) Flow cytometric analyses of
MG and MG-125b spleens were used to quantify the percent of granulocytes (GR-1+ CD19−), macrophages (F4/80+ CD68+), dendritic cells (CD11b+ CD11c+),
T cells (CD3ε+ CD19−), and B cells (CD19+ GR-1−). Total leukocyte counts in the spleen were similar between MG and MG-125b mice. (B) The percent of MPPs
and total numbers of CMPs/GMPs, MEPs, CLPs, and pre-B cells in the bone marrow were measured by ﬂow cytometry. Horizontal lines represent the means,
and each dot represents an individual mouse. Data are representative of two to three independent experiments with four to ﬁve mice per group.
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loss of function assays allowed us to determine whether inhibiting
Lin28A function would mimic speciﬁc aspects of hematopoietic
development observed on overexpressing miR-125b. Thus, we
transduced HSPC-enriched bonemarrow with Lin28A shRNA and
achieved ∼70% transduction with a twofold knockdown of Lin28A
as assessed by quantitative PCR (Fig. 6A and B), less than the level
of repression exerted by miR-125b overexpression (Fig. 4A).
Strikingly, mice reconstituted with shLin28A exhibited similar
but less dramatic features of hematopoietic development to those
features caused by overexpression ofmiR-125b at the precancerous
stage: expansion of myeloid cells (CD45+ CD11b+, CD45+ Gr1+)
and a decrease of B cells (CD19+ CD11b−) (Fig. 6 C–E). The
Lin28A knockdown mimicked the alteration of the hematopoietic
system that we observed in miR-125b overexpressers (Fig. 2A),
namely increased myeloid cells and decreased B cells (Fig. 6 C–E).
Thus, we show that Lin28A is a primary target of miR-125b in
hematopoiesis and that its levels inﬂuence development of the
hematopoietic system.
Discussion
We show here that (i) miR-125b overexpression causes a highly
invasive myeloid leukemia; (ii) in the preleukemic stage of dis-
ease, miR-125b induces a skewing of the hematopoietic system
favoring myeloid development; (iii) before terminal leukemia
development, miR-125b drastically increases CMP/GMP num-
bers; (iv) in addition to the pathological role of miR-125b, it also
physiologically regulates hematopoiesis as shown by down-regu-
lating it with a sponge construct; (v) Lin28A is a bona ﬁde primary
target of miR-125b in hematopoietic cells; and (vi) Lin28A
overexpression and knockdown mimic important aspects of miR-
125b loss of function and gain of function, respectively. We con-
clude that miR-125b physiologically regulates hematopoiesis and
constitutive overexpression of miR-125b in our experimental
system, leading to uncontrolled generation of myeloid progenitors
and mature myeloid cells that subsequently causes a myeloid
leukemia. We also conclude that the miR-125b primary target
Lin28A is an important regulator of hematopoietic development.
In this study, we observed that miR-125b overexpression
induces an aggressive myeloid leukemia that is highly invasive.
Of note, 2 of 14 mice analyzed in two cohorts exhibited signiﬁ-
cantly increased lymphoid cells as well, supporting the studies by
Enomoto et al. (2), Bousquet et al. (6), and Ooi et al. (23) that
show that miR-125b is capable of causing leukemias involving
lymphoid cell types. Interestingly, the work by Enomoto et al. (2)
conﬁrms the remarkable potency of miR-125b as an oncomiR by
showing that B cell-restricted ectopic expression of miR-125b
can drive lymphoid leukemia. In our system, miR-125b and GFP
are expressed from the same transcript. Interestingly, the GFP
intensity in the CD11b+ myeloid cells of the MG-125b mice was
much higher than the intensity of CD19+ B cells (geometric
mean ﬂuorescence of 85.2 ± 7.3 versus 15.7 ± 0.8, respectively),
suggesting that miR-125b is expressed more highly in the former
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Fig. 3. Inhibiting miR-125b function decreases hematopoietic output. Equal
numbers of sorted GFP+ MG- and MG-Sponge–transduced progenitor-
enriched bone marrow cells (BMCs) were injected into recipient animals. (A)
Total numbers of white blood cells, (B) myeloid cells, (C) granulocytes, and
(D) pre-erythroid cells were measured by ﬂow cytometry. Data represent
mean number of cells per milliliter of blood (SEM shown). P values were
calculated using unpaired Student t test. All results are representative of two
independent experiments with 9–10 animals per group.
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Fig. 4. miR-125b represses Lin28A expression
in mouse and human hematopoietic cells. (A)
Relative expression of miR-125b candidate tar-
gets in miR-125b–overexpressing progenitor-
enriched BMCs compared with MG control.
Bone marrow cells from 5-FU–treated mice were
infected with miR-125b–overexpressing vector,
and RNA was subsequently harvested for ex-
pression level analysis. The relative expression
level was measured by quantitative PCR. (B)
3′ UTR reporter analyses. The 3′ UTR of the
indicated genes was cloned into a luciferase
reporter and cotransfected with a miR-125b
expression vector. Relative luminescence of the
luciferase reporters was measured and normal-
ized to an empty vector control. The Picalm 3′
UTR, which contains no miR-125b putative
binding sites, serves as a negative control. The
2mer positive control, which consists of two
adjacent miR-125b antisense sites, is also shown.
(C ) Relative luminescence of the Lin28A 3′ UTR
reporter cotransfected with either MG or miR-
125b sponge into 293T cells. (D) Protein ex-
pression of Lin28A transduced with either MGP
empty vector or MGP expressing miR-125b-1, miR-125b-2, or a miR-125b seed mutant in K562 cells. Protein levels were obtained by Western blot, and
β-actin was included as a loading control. All data shown represent mean with SEM of two to three independent experiments. *P < 0.02, **P < 0.01.
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lineages. This ﬁnding might explain the predominance of mye-
loid leukemia observed in our system. Of importance, miR-125b
has been found to be overexpressed in a variety of human leu-
kemias, including acute myeloid leukemia (1, 2), chronic myeloid
leukemia (2), acute megakaryocytic leukemia (3), and childhood
acute lymphoblastic leukemia (2, 4), suggesting that deregulated
miR-125b expression in different contexts can lead to distinct
types of cancer.
Interestingly, the work by Ooi et al. (23) showed that recipient
mice reconstituted with miR-125b overexpression display ele-
vated HSC numbers. Although we did not observe an increase in
HSC numbers, our study does not exclude that miR-125b regu-
lates HSC development; the discrepancy likely reﬂects differ-
ences in experimental models used between the two studies. The
work by Ooi et al. (23) overexpressed miR-125b in puriﬁed HSCs
using a lentiviral system, whereas we ectopically expressed the
microRNA in unsorted progenitor-enriched bone marrow he-
matopoietic cells using a retroviral system. It is possible that our
retroviral system may not adequately overexpress miR-125b in
HSCs to observe a phenotype in these cells. Nonetheless, we
show here that miR-125b overexpression is capable of inducing
an aggressive myeloid leukemia and increases levels of MPPs,
CMPs/GMPs, MEPs, and CLPs independent of HSC numbers.
In the future, it will be interesting to investigate whether miR-
125b overexpression drives tumorigenesis in myeloid progenitors
and/or mature myeloid cells.
We show here that miR-125b is an important regulator of
hematopoiesis both physiologically and pathologically. Searching
for a mechanism by which miR-125b exerts its effects on the
hematopoietic system, we found that the direct target of miR-
125b, Lin28A, is also a regulator of hematopoiesis. The miR-
125b seed sequence within 3′UTR of Lin28A has been previously
identiﬁed and shown to be functionally important for miR-125b
repression (20). In our study, manipulating Lin28A expression
levels in mice mimicked the hematopoietic phenotypes of those
mice with modulated miR-125b levels. Of note, shRNA-mediated
knockdown of Lin28A was less effective than miR-125b–medi-
ated knockdown, indicating that better speciﬁc knockdown of
Lin28Amight more precisely mimic the miR-125b overexpression
phenotype. Although we show Lin28A as a miR-125b target im-
portant for hematopoiesis, we do not exclude that other miR-125b
targets might play a role as well. Indeed, the work by Le et al. (24)
has recently showed that miR-125b regulates a panel of genes in
the p53 pathway. Potentially, Lin28A knockdown by miR-125b
may help set the stage for myeloid leukemia.We did not, however,
observe obvious signs of leukemia in the shLin28A mice at 3 mo
after bone marrow transplantation, suggesting that either cancer
will occur later or repression of other targets, such as the proa-
poptotic genes Bak1, Trp53inp1 and BMF, may collaborate with
Lin28A inhibition during miR-125b–mediated cancer.
In summary, this work links two molecules shown in different
contexts to be important in development, miR-125b and Lin28A,
and indicates that their interaction serves as a fundamental
regulator of hematopoietic physiology and pathology. Indeed,
the interplay between miR-125b and Lin28A is one that might be
toggled therapeutically to ameliorate hematopoietic disorders
such as leukemia and bone marrow failure.
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Fig. 5. Lin28A overexpression inhibits hematopoiesis. Recipients were
transplanted with progenitor-enriched BMCs transduced with MIG-Lin28A or
MIG. Five weeks postreconstitution, the number of (A) white blood cells, (B)
myeloid cells, (C) granulocytes, and (D) erythrocytes per milliliter in the blood
weremeasured by ﬂow cytometry.We did not observe an increase in B cells in
the MIG-Lin28A animals. Data are pooled from two independent groups of
MIG-Lin28A animals, each with seven to eight animals, and compared with
MIG (six animals). Data shown graphically represent the mean and SEM.
A
C D E
B
Fig. 6. Inhibition of Lin28A increases the
number of myeloid cells but decreases B cells.
(A) Flow cytometry of progenitor-enriched
bone marrow transduced with MG-Lin28A
shRNA or MG control vector was performed,
and the percent GFP+ cells is indicated. (B)
Lin28A mRNA expression was obtained by
quantitative PCR on the samples shown in A,
and the results were normalized to L32. Rep-
resentative of two independent experiments
with four samples per group. (C) Total myeloid,
(D) granulocytes, and (E) B cells were measured
from blood 5 wk postreconstitution of bone
marrow with seven to eight animals per group.
Data shown represent mean and SEM. P values
are indicated.
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Methods
Cell Culture. 293T cells were cultured in complete DMEM with 10% FBS, 100
units/mL penicillin, and 100 units/mL streptomycin. K562 cells and splenocytes
from mice were cultured in complete RPMI with 10% FBS, 100 units/mL
penicillin, 100 units/mL streptomycin, and 50 μM 2-Mercaptoethanol.
DNA Constructs. The retroviral vectorsMG,MGP,MGP-125b-1, andMGP-125b-
2 have been described previously (5, 25–27). Both Lin28A shRNA and MGP-
125b-mutant were cloned using an miR-155 arms and loop format, which
has been previously described (5, 25–27). The Lin28A shRNA sequence was
predicted using the Invitrogen BlockiT RNAi Designer. The 3′ UTRs for mouse
Lin28A, Trp53inp1, Bak1, and BMF as well as the antisense 2mer were cloned
downstream of luciferase in the pMIR-REPORT vector (Ambion). For the
Lin28A overexpression vector, the mouse Lin28A coding sequence (Open
Biosystems) was cloned downstream of the LTR and preceding the IRES-GFP
of the MIG vector (22). All primers are listed in Table S1.
Retroviral Transduction and Bone Marrow Reconstitution Experiments. C57BL/6
mice were bred and housed in the Caltech Ofﬁce of Laboratory Animal
Resources facility. The Caltech Institutional Animal Care and Use Committee
approved all experiments related to mice. Virus production and re-
constitution experiments were performed as previously described (5, 25–27).
K562 cells were transduced with vesicular stomatitis virus glycoprotein–
pseudotyped MGP, MGP-125b-1, MGP-125b-2, and MGP-125b-Mut as de-
scribed previously (5).
Cell Counting and Flow Cytometry. Cells were counted using a Coulter Counter
(Beckman Coulter) or a MACSQuant ﬂow cytometer (Miltenyi). Absolute cell
counts in the blood were obtained by FACS staining equivalent volumes of
blood, resuspending the stained samples in equivalent volumes of FACS
buffer, and running equal volumes of each sample using theMACSQuant. For
ﬂow cytometry, cells were harvested and homogenized, and red blood cells
were lysed. Cells were stained with the following ﬂuorophore-conjugated
antibodies that were purchased from Biolegend, Ebioscience, or BD Phar-
mingen and assayed using MACSQuant (Miltenyi) or a FACSCalibur (Becton
Dickinson). All data were analyzed with FlowJo software (Treestar). Speciﬁc
gating strategies are available on request.
Cell Sorting for Sponge Reconstitution. 5-FU–enriched bone marrow was
transduced with retroviral vectors as previously described (5, 25–27). Before
i.v. injection into mice, GFP-positive MG- and MG-Sponge–transduced sam-
ples were sorted using an iCyt cell sorter. Equal numbers of cells were then
injected into lethally irradiated recipient animals.
Target Analysis. Predicted miR-125b targets in Homo sapiens were down-
loaded from Targetscan and rank-ordered by their probability of conserved
targeting (PCT) scores. Repeated target genes were removed from this list
using a PERL script (available on request). Literature search was performed
on the resulting list to identify candidate target genes. For one target
(Lin28A), the 3′ UTR for the mouse version of the gene was obtained and
aligned with miR-125b using TargetScan.
Luciferase Reporter Assays. Reporter assays to measure microRNA-based re-
pression of target 3′ UTRs were performed as previously described (25–27).
For derepression assays with the sponge construct, we added MG (empty
vector) or MG-Sponge to the transfection mix. After 24 h, cells were lysed
with Passive Lysis Buffer (Promega), and luciferase assays were performed as
previously described (25–27).
RNA Preparation and Quantitation. RNAwas isolatedwithTRIzol (Invitrogen) as
per the manufacturer’s instructions. We performed SYBR Green-based
(Quanta Biosciences) quantitative real-time PCR with a 7300 Real-Time PCR
machine (Applied Biosystems) to assay mRNA levels. A Taqman approach was
used to quantify miR-125b and snoRNA-202 expressions (Applied Biosystems).
All mRNA levels were normalized to L32, whereas microRNA-125b levels were
normalized to snoRNA-202. Sequence-speciﬁc primers are listed in Table S1.
Immunoblotting. Total cell extracts were fractionated by electrophoresis on
a 12% SDS polyacrylamide gel and electroblotted onto a Trans-Blot nitro-
cellulose membrane with a semidry transfer apparatus. Protein detection was
performed using the following antibodies: Lin28A (A177; Cell Signaling),
β-Actin (A1978; Sigma), anti-rabbit HRP-conjugated secondary antibody
(Santa Cruz Biotechnology), and anti-mouse HRP-conjugated secondary an-
tibody (Santa Cruz Biotechnology).
Statistical Tests. Statistical tests were performed using Graphpad PRISM
software or Microsoft Excel. The two-tailed Student t test was used to de-
termine P values.
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